Literature DB >> 10438838

Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection.

T Murakami1, T Y Zhang, Y Koyanagi, Y Tanaka, J Kim, Y Suzuki, S Minoguchi, H Tamamura, M Waki, A Matsumoto, N Fujii, H Shida, J A Hoxie, S C Peiper, N Yamamoto.   

Abstract

We recently reported that a cationic peptide, T22 ([Tyr(5,12), Lys(7)]-polyphemusin II), specifically inhibits human immunodeficiency virus type 1 (HIV-1) infection mediated by CXCR4 (T. Murakami et al., J. Exp. Med. 186:1389-1393, 1997). Here we demonstrate that T22 effectively inhibits replication of T-tropic HIV-1, including primary isolates, but not of non-T-tropic strains. By using a panel of chimeric viruses between T- and M-tropic HIV-1 strains, viral determinants for T22 susceptibility were mapped to the V3 loop region of gp120. T22 bound to CXCR4 and interfered with stromal-cell-derived factor-1alpha-CXCR4 interactions in a competitive manner. Blocking of anti-CXCR4 monoclonal antibodies by T22 suggested that the peptide interacts with the N terminus and two of the extracellular loops of CXCR4. Furthermore, the inhibition of cell-cell fusion in cells expressing CXCR4/CXCR2 chimeric receptors suggested that determinants for sensitivity of CXCR4 to T22 include the three extracellular loops of the coreceptor.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10438838      PMCID: PMC104275     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  70 in total

1.  Mutational analysis of human immunodeficiency virus type 1 (HIV-1) accessory genes: requirement of a site in the nef gene for HIV-1 replication in activated CD4+ T cells in vitro and in vivo.

Authors:  Y Kawano; Y Tanaka; N Misawa; R Tanaka; J I Kira; T Kimura; M Fukushi; K Sano; T Goto; M Nakai; T Kobayashi; N Yamamoto; Y Koyanagi
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.

Authors:  A Trkola; T Dragic; J Arthos; J M Binley; W C Olson; G P Allaway; C Cheng-Mayer; J Robinson; P J Maddon; J P Moore
Journal:  Nature       Date:  1996-11-14       Impact factor: 49.962

3.  CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.

Authors:  L Wu; N P Gerard; R Wyatt; H Choe; C Parolin; N Ruffing; A Borsetti; A A Cardoso; E Desjardin; W Newman; C Gerard; J Sodroski
Journal:  Nature       Date:  1996-11-14       Impact factor: 49.962

4.  Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 and CXCR4 domains.

Authors:  Z Lu; J F Berson; Y Chen; J D Turner; T Zhang; M Sharron; M H Jenks; Z Wang; J Kim; J Rucker; J A Hoxie; S C Peiper; R W Doms
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

5.  Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses.

Authors:  J Rucker; A L Edinger; M Sharron; M Samson; B Lee; J F Berson; Y Yi; B Margulies; R G Collman; B J Doranz; M Parmentier; R W Doms
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

6.  The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection.

Authors:  F Cocchi; A L DeVico; A Garzino-Demo; A Cara; R C Gallo; P Lusso
Journal:  Nat Med       Date:  1996-11       Impact factor: 53.440

7.  Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist.

Authors:  G Simmons; P R Clapham; L Picard; R E Offord; M M Rosenkilde; T W Schwartz; R Buser; T N Wells; A E Proudfoot
Journal:  Science       Date:  1997-04-11       Impact factor: 47.728

8.  CD4-independent infection by HIV-2 is mediated by fusin/CXCR4.

Authors:  M J Endres; P R Clapham; M Marsh; M Ahuja; J D Turner; A McKnight; J F Thomas; B Stoebenau-Haggarty; S Choe; P J Vance; T N Wells; C A Power; S S Sutterwala; R W Doms; N R Landau; J A Hoxie
Journal:  Cell       Date:  1996-11-15       Impact factor: 41.582

9.  A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor.

Authors:  B J Doranz; K Grovit-Ferbas; M P Sharron; S H Mao; M B Goetz; E S Daar; R W Doms; W A O'Brien
Journal:  J Exp Med       Date:  1997-10-20       Impact factor: 14.307

10.  STRL33, A novel chemokine receptor-like protein, functions as a fusion cofactor for both macrophage-tropic and T cell line-tropic HIV-1.

Authors:  F Liao; G Alkhatib; K W Peden; G Sharma; E A Berger; J M Farber
Journal:  J Exp Med       Date:  1997-06-02       Impact factor: 14.307

View more
  19 in total

1.  Galectin-1-specific inhibitors as a new class of compounds to treat HIV-1 infection.

Authors:  Christian St-Pierre; Michel Ouellet; Denis Giguère; Reiko Ohtake; René Roy; Sachiko Sato; Michel J Tremblay
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

Review 2.  Mechanisms and modifications of naturally occurring host defense peptides for anti-HIV microbicide development.

Authors:  Colleen R Eade; Matthew P Wood; Alexander M Cole
Journal:  Curr HIV Res       Date:  2012-01-01       Impact factor: 1.581

3.  Multifaceted mechanisms of HIV-1 entry inhibition by human α-defensin.

Authors:  Lusine H Demirkhanyan; Mariana Marin; Sergi Padilla-Parra; Changyou Zhan; Kosuke Miyauchi; Maikha Jean-Baptiste; Gennadiy Novitskiy; Wuyuan Lu; Gregory B Melikyan
Journal:  J Biol Chem       Date:  2012-06-25       Impact factor: 5.157

Review 4.  Anti-HIV drug development through computational methods.

Authors:  Wan-Gang Gu; Xuan Zhang; Jun-Fa Yuan
Journal:  AAPS J       Date:  2014-04-24       Impact factor: 4.009

5.  CCR5, GPR15, and CXCR6 are major coreceptors of human immunodeficiency virus type 2 variants isolated from individuals with and without plasma viremia.

Authors:  H Blaak; P H M Boers; R A Gruters; H Schuitemaker; M E van der Ende; A D M E Osterhaus
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

6.  Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro.

Authors:  Jia Ma; Suzanne Kennedy-Stoskopf; Jesse M Jaynes; Linda M Thurmond; Wayne A Tompkins
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

7.  The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.

Authors:  Tsutomu Murakami; Sei Kumakura; Toru Yamazaki; Reiko Tanaka; Makiko Hamatake; Kazu Okuma; Wei Huang; Jonathan Toma; Jun Komano; Mikiro Yanaka; Yuetsu Tanaka; Naoki Yamamoto
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

8.  CAF-mediated human immunodeficiency virus (HIV) type 1 transcriptional inhibition is distinct from alpha-defensin-1 HIV inhibition.

Authors:  Theresa Li-Yun Chang; Fleur François; Arevik Mosoian; Mary E Klotman
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

9.  In vivo evolution of X4 human immunodeficiency virus type 1 variants in the natural course of infection coincides with decreasing sensitivity to CXCR4 antagonists.

Authors:  Evelien H B Stalmeijer; Ronald P Van Rij; Brigitte Boeser-Nunnink; Janny A Visser; Marloes A Naarding; Dominique Schols; Hanneke Schuitemaker
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

10.  Exploratory studies on development of the chemokine receptor CXCR4 antagonists toward downsizing.

Authors:  Hirokazu Tamamura; Hiroshi Tsutsumi; Wataru Nomura; Nobutaka Fujii
Journal:  Perspect Medicin Chem       Date:  2008-02-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.